WHAT IS CLAIMED IS:

1. A compound of Formula *I*:



I

or a pharmaceutically-acceptable salt or solvate thereof, wherein:

R_1 is at each occurrence selected from the group consisting of halogen, optionally-substituted C_{1-6} alkyl, amino, nitro and cyano;

n is an integer from 1 to 3;

X is -O-, -S-, -NH-, -$NHCH_2$-, -CH_2NH-, -CH_2-, -CH_2O-, -OCH_2-, -CH_2S- or -SCH_2-;

R_2 is



wherein:

m is an integer from 2 to 4;

R_4 and R_5 are independently selected from the group consisting of hydrogen and optionally-substituted C_{1-6} alkyl; or R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from -O-, -S-, and -NR_6-, wherein R_6 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl or C_{1-6} hydroxyalkyl; and

R_3 is hydrogen, optionally-substituted C_{1-6} alkyl,



wherein:

R_7 is oxygen or sulfur; and

R_8 is selected from the group consisting of optionally-substituted C_{1-6} alkyl, an optionally-substituted C_{3-8} carbocyclic ring system and optionally-substituted C_{6-10} aryl,

or R_3 is



wherein:

R_7 is oxygen or sulfur;

Z is -O- or -NH-;

p is an integer from 0 to 4; and

R_9 is selected from the group consisting of optionally-substituted C_{1-6} alkyl, an optionally-substituted C_{3-8} carbocyclic ring system, optionally-substituted C_{6-10} aryl, optionally-substituted heteroaryl and optionally-substituted heterocycle, wherein the heterocycle is saturated or partially unsaturated;

provided that,

when R_4 and R_5 are independently hydrogen or C_{1-2} alkyl, or when R_4 and R_5 together with the nitrogen to which they are attached form pyrrolidinyl, then X is not -S-;

when X is $-CH_2O-$ and R_3 is hydrogen or methyl, then at least one of R_4 or R_5 is not C_{3-5} alkyl; and

when X is -O- and R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, then R_8 is not a C_3 carbocyclic ring system, and R_9 is not C_{3-5} alkyl, phenyl, dihalophenyl or (C_{1-2} alkyl)phenyl.

2. The compound according to claim 1, wherein *n* is 1.

3. The compound according to claim 1, wherein R_1 is positioned *meta* relative to X.

4. The compound according to claim 1, wherein R_1 is C_{1-6} haloalkyl.

5. The compound according to claim 1, wherein X include -O-.

6. The compound according to claim 1, wherein $-CH_2-NR_2R_3$ is positioned *meta* relative to X.

7. The compound according to claim 1, wherein *m* is 2.

8. The compound according to claim 1, wherein R_4 and R_5 together with the nitrogen to which they are attached form a piperidyl ring.

9. The compound according to claim 1, wherein R_3 is hydrogen or optionally-substituted C_{1-6} alkyl.

10. The compound according to claim 9, wherein R_3 is hydrogen.

11. The compound according to claim 1, wherein R_3 is  .

12. The compound according to claim 11, wherein R_7 is oxygen.

13. The compound according to claim 11, wherein R_8 is C_{1-6} alkyl, C_{5-6} cycloalkyl or optionally-substituted phenyl, wherein said optionally-substituted phenyl is optionally substituted once with halogen or C_{1-4} alkyl.

14. The compound according to claim 11, wherein R_8 is acetyl, cyclopentanecarbonyl or *p*-fluorobenzoyl.

15. The compound according to claim 1, wherein R_3 is



16. The compound according to claim 15, wherein R_7 is oxygen.

17. The compound according to claim 15, wherein Z is -NH-.

18. The compound according to claim 15, wherein *p* is zero, 1, 2 or 3.

19. The compound according to claim 15, wherein R_9 is C_{5-6} cycloalkyl, optionally-substituted phenyl and 5- to 6-membered saturated or partially unsaturated heterocycle, wherein said optionally-substituted phenyl is optionally substituted once with halogen or C_{1-4} alkyl.

20. The compound according to claim 15, wherein R_3 is cyclohexylamino-carbonyl, 2-fluorophenylaminocarbonyl or 3-(morpholin-4-yl)-propylamino-thiocarbonyl.

21. The compound according to claim 1, wherein:

R_3 is hydrogen or optionally-substituted C_{1-6} alkyl;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and -NR_6-, wherein R_6 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl or C_{1-6} hydroxyalkyl; and

X is -O-, $-CH_2-O-$ or $-CH_2-S-$.

22. The compound according to claim 1, wherein:

R_3 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl or C_{1-6} alkyloxy(C_{1-6})alkyl;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms selected from the group consisting of -O-, -S-, and $-NR_6-$, wherein R_6 is hydrogen or C_{1-6} alkyl;

n is 1 or 2;

R_1 is halogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

X is -O- or $-CH_2-O-$; and

m is 2 or 3.

23. The compound according to claim 1, wherein:

R_3 is hydrogen or C_{1-6} alkyl;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 additional heteroatom independently selected from the group consisting of -O-, -S- and $-NR_6-$, wherein R_6 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl or C_{1-6} hydroxyalkyl;

n is 1;

R_1 is C_{1-6} haloalkyl;

X is -O-; and

m is 2.

24. The compound according to claim 1, wherein:

R_3 is hydrogen or optionally-substituted C_{1-6} alkyl;

one of R_4 or R_5 is selected from the group consisting of hydrogen and optionally-substituted C_{1-6} alkyl, and the other is selected from the group consisting of hydrogen, optionally-substituted C_{1-2} alkyl and optionally-substituted C_6 alkyl; and

X is -O-, $-CH_2-O-$ or $-CH_2-S-$.

25. The compound according to claim 1, wherein:

R_3 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl or C_{1-6} alkyloxy(C_{1-6})alkyl;

one of R_4 or R_5 is selected from the group consisting of hydrogen, C_{1-6} alkyl and C_{1-6} haloalkyl, and the other is selected from the group consisting of hydrogen, C_{1-2} alkyl, C_6 alkyl, C_{1-2} haloalkyl and C_6 haloalkyl;

n is 1 or 2;

R_1 is halogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

X is -O- or $-CH_2-O-$; and

m is 2 or 3.

26. The compound according to claim 1, wherein:

R_3 is hydrogen or C_{1-6} alkyl;

R_4 and R_5 are independently selected from the group consisting of hydrogen and C_{1-6} alkyl;

n is 1;

R_1 is C_{1-6} haloalkyl;

X is -O-; and

m is 2.

27. The compound according to claim 1, wherein R_3 is  , wherein:

R_7 is oxygen or sulfur;

R_8 is optionally-substituted C_{1-6} alkyl, optionally-substituted C_{5-8} cycloalkyl or optionally-substituted C_{6-10} aryl;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of

-O-, -S- and -NR_6-, wherein R_6 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl or C_{1-6} hydroxyalkyl; and

X is -O-, -CH_2-O- or -CH_2-S-.

28. The compound according to claim 1, wherein R_3 is  , wherein:

R_7 is oxygen;

R_8 is C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, optionally-substituted C_{5-6} cycloalkyl or optionally-substituted phenyl;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms selected from the group consisting of -O-, -S-, and -NR_6-, wherein R_6 is hydrogen or C_{1-6} alkyl;

n is 1 or 2;

R_1 is halogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

X is -O- or - CH_2-O -; and

m is 2 or 3.

29. The compound according to claim 1, wherein R_3 is  , wherein:

R_7 is oxygen;

R_8 is C_{1-6} alkyl, C_{5-6} cycloalkyl or phenyl, wherein the phenyl is substituted with zero, 1 or 2 groups independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkyloxy(C_{1-6})alkyl, amino(C_{1-6})alkyl, hydroxy, nitro and amino;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 additional

heteroatom independently selected from the group consisting of -O-, -S- and $-NR_6-$, wherein R_6 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl or C_{1-6} hydroxyalkyl;

n is 1;

R_1 is C_{1-6} haloalkyl;

X is -O-; and

m is 2.

30. The compound according to claim 1, wherein R_3 is  , wherein:

R_7 is oxygen or sulfur;

R_8 is optionally-substituted C_{1-6} alkyl, optionally-substituted C_{3-8} cycloalkyl or optionally-substituted C_{6-10} aryl;

R_4 and R_5 are independently selected from the group consisting of hydrogen and optionally-substituted C_{1-6} alkyl; and

X is -O-, $-CH_2-O-$ or $-CH_2-S-$.

31. The compound according to claim 1, wherein R_3 is  , wherein:

R_7 is oxygen;

R_8 is C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, optionally-substituted C_{5-6} cycloalkyl or optionally-substituted phenyl;

R_4 and R_5 are independently selected from hydrogen, C_{1-6} alkyl and C_{1-6} haloalkyl;

n is 1 or 2;

R_1 is halogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

X is -O- or $-CH_2-O-$; and

m is 2 or 3.

32. The compound according to claim 1, wherein R_3 is  , wherein:

R_7 is oxygen;

R_8 is C_{1-6} alkyl, C_{5-6} cycloalkyl or phenyl, wherein the phenyl is substituted with zero, 1 or 2 groups independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkyloxy(C_{1-6})alkyl, amino(C_{1-6})alkyl, hydroxy, nitro and amino;

R_4 and R_5 are independently selected from the group consisting of hydrogen and C_{1-6} alkyl;

n is 1;

R_1 is C_{1-6} haloalkyl;

X is -O-; and

m is 2.

33. The compound according to claim 1, wherein R_3 is  , wherein:

R_9 is optionally-substituted C_{1-2} alkyl, optionally-substituted C_6 alkyl, optionally-substituted C_{3-8} cycloalkyl, substituted C_{6-10} aryl, optionally-substituted heteroaryl or optionally-substituted saturated or partially unsaturated heterocycle;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and -NR_6-, wherein R_6 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl or C_{1-6} hydroxyalkyl; and

X is -O-, -CH_2-O- or -CH_2-S-.

34. The compound according to claim 1, wherein R_3 is  , wherein:

R_7 is oxygen;

Z is -NH-;

p is zero, 1, 2 or 3;

R_9 is C_{1-2} alkyl, C_6 alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, optionally-substituted C_{5-6} cycloalkyl, substituted phenyl or optionally-substituted 5- to 6-membered saturated or partially unsaturated heterocycle;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms selected from the group consisting of -O-, -S-, and $-NR_6-$, wherein R_6 is hydrogen or C_{1-6} alkyl;

n is 1 or 2;

R_1 is halogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

X is -O- or $-CH_2-O-$; and

m is 2 or 3.

35. The compound according to claim 1, wherein R_3 is  , wherein:

R_7 is oxygen;

Z is -NH-;

p is zero, 1, 2 or 3;

R_9 is C_{5-6} cycloalkyl, substituted phenyl or 5- to 6-membered saturated or partially unsaturated heterocycle, where the substituted phenyl is phenyl substituted with 1 or 2 groups independently selected from the group consisting of halogen, C_{3-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkyloxy(C_{1-6})alkyl, amino(C_{1-6})alkyl, hydroxy, nitro and amino, and where the substituted phenyl is not dihalophenyl;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 additional heteroatom independently selected from -O-, -S- and -NR_6-, wherein R_6 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl or C_{1-6} hydroxyalkyl; *n* is 1;

R_1 is C_{1-6} haloalkyl;

X is -O-; and

m is 2.

36. The compound according to claim 1, wherein R_3 is  , wherein:

R_9 is optionally-substituted C_{1-6} alkyl, optionally-substituted C_{3-8} cycloalkyl, optionally-substituted C_{6-10} aryl, optionally-substituted heteroaryl or optionally-substituted saturated or partially unsaturated heterocycle;

R_4 and R_5 are independently selected from the group consisting of hydrogen and optionally-substituted C_{1-6} alkyl; and

X is -O-, -CH_2-O- or -CH_2-S-.

37. The compound according to claim 1, wherein R_3 is  , wherein:

R_7 is oxygen;

Z is -NH-;

p is zero, 1, 2 or 3;

R_9 is C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, optionally-substituted C_{5-6} cycloalkyl, optionally-substituted phenyl or optionally-substituted 5- to 6-membered saturated or partially unsaturated heterocycle;

R_4 and R_5 are independently selected from the group consisting of hydrogen, C_{1-6} alkyl and C_{1-6} haloalkyl;

n is 1 or 2;

R_1 is halogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

X is -O- or -CH_2-O-; and

m is 2 or 3.

38. The compound according to claim 1, wherein R_3 is  , wherein:

R_7 is oxygen;

Z is -NH-;

p is zero, 1, 2 or 3;

R_9 is C_{5-6} cycloalkyl, optionally-substituted phenyl or 5- to 6-membered saturated or partially unsaturated heterocycle, wherein the phenyl is substituted with zero, 1 or 2 groups independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkyloxy(C_{1-6})alkyl, amino(C_{1-6})alkyl, hydroxy, nitro and amino;

R_4 and R_5 are independently selected from the group consisting of hydrogen and C_{1-6} alkyl;

n is 1;

R_1 is C_{1-6} haloalkyl;

X is -O-; and

m is 2.

39. A compound selected from the group consisting of

N-(2-piperidin-1-ylethyl)-*N*-[3-(3-trifluoromethylphenoxy)benzyl]amine;

N-(2-piperidin-1-ylethyl)-*N*-[3-(3-trifluoromethylphenoxy)benzyl]-acetamide;

N-(2-piperidin-1-ylethyl)-*N*-[3-(3-trifluoromethylphenoxy)benzyl]-cyclopentane carboxamide;

N-(2-piperidin-1-ylethyl)-*N*-[3-(3-trifluoromethylphenoxy)benzyl]-4-fluorobenzamide;

N'-cyclohexyl-*N*-(2-piperidin-1-ylethyl)-*N*-[3-(3-trifluoromethylphenoxy)-benzyl]urea;

N'-(2-fluorophenyl)-*N*-(2-piperidin-1-ylethyl)-*N*-[3-(3-trifluoromethyl-phenoxy)benzyl]urea; and

N'-[3-(morpholin-4-yl)propyl]-*N*-(2-piperidin-1-ylethyl)-*N*-[3-(3-trifluoromethylphenoxy)benzyl]thiourea;
and pharmaceutically-acceptable salts thereof.

40. A pharmaceutical composition comprising the compound according to claim 1, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier or diluent.

41. A method for treating, preventing or ameliorating a disorder responsive to blockage of sodium ion channels in a mammal suffering therefrom, comprising administering to said mammal in need of such treatment an effective amount of a compound of Formula ***I***



I

or a pharmaceutically-acceptable salt or solvate thereof, wherein:

R_1 is at each occurrence independently selected from the group consisting of hydrogen, halogen, optionally-substituted C_{1-6} alkyl, amino, nitro and cyano;

n is an integer from 1 to 3;

X is -O-, -S-, -NH-, -$NHCH_2$-, -CH_2NH-, -CH_2-, -CH_2O-, -OCH_2-, -CH_2S- or -SCH_2-;

R_2 is



wherein:

m is an integer from 2 to 4;

R_4 and R_5 are independently selected from hydrogen and optionally-substituted C_{1-6} alkyl; or R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from -O-, -S-, and $-NR_6-$, wherein R_6 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl or C_{1-6} hydroxyalkyl; and

R_3 is hydrogen, optionally-substituted C_{1-6} alkyl,



wherein:

R_7 is oxygen or sulfur; and

R_8 is selected from optionally-substituted C_{1-6} alkyl, an optionally-substituted C_{3-8} carbocyclic ring system and optionally-substituted C_{6-10} aryl, or R_3 is



wherein:

R_7 is oxygen or sulfur;

Z is –O- or –NH-;

p is an integer from zero to 4; and

R_9 is selected from optionally-substituted C_{1-6} alkyl, an optionally-substituted C_{3-8} carbocyclic ring system, optionally-substituted C_{6-10} aryl, optionally-

substituted heteroaryl and optionally-substituted heterocycle, wherein the heterocycle is saturated or partially unsaturated.

42. The method according to claim 41, wherein:

R_3 is hydrogen or optionally-substituted C_{1-6} alkyl;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and $-NR_6-$, wherein R_6 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl or C_{1-6} hydroxyalkyl; and

X is -O-, -S-, $-CH_2-O-$ or $-CH_2-S-$.

43. The method according to claim 41, wherein:

R_3 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl or C_{1-6} alkyloxy(C_{1-6})alkyl;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms selected from the group consisting of -O-, -S-, and $-NR_6-$, wherein R_6 is hydrogen or C_{1-6} alkyl;

n is 1 or 2;

R_1 is halogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

X is -O- or -S-; and

m is 2 or 3.

44. The method according to claim 41, wherein:

R_3 is hydrogen or C_{1-6} alkyl;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 additional heteroatom independently selected from the group consisting of -O-, -S- and $-NR_6-$, wherein R_6 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl or C_{1-6} hydroxyalkyl;

n is 1;

R_1 is C_{1-6} haloalkyl;

X is -O-; and

m is 2.

45. The method according to claim 41, wherein:

R_3 is hydrogen or optionally-substituted C_{1-6} alkyl;

R_4 and R_5 are independently selected from the group consisting of hydrogen and optionally-substituted C_{1-6} alkyl; and

X is -O-, -S-, $-CH_2-O-$ or $-CH_2-S-$.

46. The method according to claim 41, wherein:

R_3 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl or C_{1-6} alkyloxy(C_{1-6})alkyl;

R_4 and R_5 are independently selected from the group consisting of hydrogen, C_{1-6} alkyl and C_{1-6} haloalkyl;

n is 1 or 2;

R_1 is halogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

X is -O- or -S-; and

m is 2 or 3.

47. The method according to claim 41, wherein:

R_3 is hydrogen or C_{1-6} alkyl;

R_4 and R_5 are independently selected from the group consisting of hydrogen and C_{1-6} alkyl;

n is 1;

R_1 is C_{1-6} haloalkyl;

X is -O-; and

m is 2.

48. The method according to claim 41, wherein R_3 is  , wherein:

R_7 is oxygen or sulfur;

R_8 is optionally-substituted C_{1-6} alkyl, optionally-substituted C_{3-8} cycloalkyl or optionally-substituted C_{6-10} aryl;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of the group consisting of -O-, -S- and $-NR_6-$, wherein R_6 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl or C_{1-6} hydroxyalkyl; and

X is -O-, -S-, $-CH_2-O-$ or $-CH_2-S-$.

49. The method according to claim 41, wherein R_3 is  , wherein:

R_7 is oxygen;

R_8 is C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, optionally-substituted C_{5-6} cycloalkyl or optionally-substituted phenyl;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms selected from the group consisting of -O-, -S-, and $-NR_6-$, wherein R_6 is hydrogen or C_{1-6} alkyl;

n is 1 or 2;

R_1 is halogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

X is -O- or -S-; and

m is 2 or 3.

50. The method according to claim 41, wherein R_3 is  , wherein:

R_7 is oxygen;

R_8 is C_{1-6} alkyl, C_{5-6} cycloalkyl or phenyl, wherein the phenyl is substituted with zero, 1 or 2, groups independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkyloxy(C_{1-6})alkyl, amino(C_{1-6})alkyl, hydroxy, nitro and amino;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 additional heteroatom independently selected from the group consisting of -O-, -S- and -NR_6-, wherein R_6 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl or C_{1-6} hydroxyalkyl;

n is 1;

R_1 is C_{1-6} haloalkyl;

X is -O-; and

m is 2.

51. The method according to claim 41, wherein R_3 is  , wherein:

R_7 is oxygen or sulfur;

R_8 is optionally-substituted C_{1-6} alkyl, optionally-substituted C_{3-8} cycloalkyl or optionally-substituted C_{6-10} aryl;

R_4 and R_5 are independently selected from the group consisting of hydrogen and optionally-substituted C_{1-6} alkyl; and

X is -O-, -S-, -CH_2-O- or -CH_2-S-.

52. The method according to claim 41, wherein R_3 is  , wherein:

R_7 is oxygen;

R_8 is C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, optionally-substituted C_{5-6} cycloalkyl or optionally-substituted phenyl;

R_4 and R_5 are independently selected from the group consisting of hydrogen, C_{1-6} alkyl and C_{1-6} haloalkyl;

n is 1 or 2;

R_1 is halogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

X is -O- or -S-; and

m is 2 or 3.

53. The method according to claim 41, wherein R_3 is  , wherein:

R_7 is oxygen;

R_8 is C_{1-6} alkyl, C_{5-6} cycloalkyl or phenyl, wherein the phenyl is substituted with zero, 1 or 2 groups independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkyloxy(C_{1-6})alkyl, amino(C_{1-6})alkyl, hydroxy, nitro and amino;

R_4 and R_5 are independently selected from the group consisting of hydrogen and C_{1-6} alkyl;

n is 1;

R_1 is C_{1-6} haloalkyl;

X is -O-; and

m is 2.

54. The method according to claim 41, wherein R_3 is  , wherein:

R_9 is optionally-substituted C_{1-6} alkyl, optionally-substituted C_{3-8} cycloalkyl, optionally-substituted C_{6-10} aryl, optionally-substituted heteroaryl or optionally-substituted saturated or partially unsaturated heterocycle;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms independently selected from the group consisting of -O-, -S- and $-NR_6-$, wherein R_6 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl or C_{1-6} hydroxyalkyl; and

X is -O-, -S-, $-CH_2-O-$ or $-CH_2-S-$.

55. The method according to claim 41, wherein R_3 is  , wherein:

R_7 is oxygen;

Z is -NH-;

p is zero, 1, 2 or 3;

R_9 is C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, optionally-substituted C_{5-6} cycloalkyl, optionally-substituted phenyl or optionally-substituted 5- to 6-membered saturated or partially unsaturated heterocycle;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 or 2 additional heteroatoms selected from the group consisting of -O-, -S-, and $-NR_6-$, wherein R_6 is hydrogen or C_{1-6} alkyl;

n is 1 or 2;

R_1 is halogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

X is -O- or -S-; and

m is 2 or 3.

56. The method according to claim 41, wherein R_3 is  , wherein:

R_7 is oxygen;

Z is -NH-;

p is zero, 1, 2 or 3;

R_9 is C_{5-6} cycloalkyl, optionally-substituted phenyl or 5- to 6-membered saturated or partially unsaturated heterocycle, wherein the phenyl is substituted with zero, 1 or 2 groups independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkyloxy(C_{1-6})alkyl, amino(C_{1-6})alkyl, hydroxy, nitro and amino;

R_4 and R_5 together with the nitrogen to which they are attached form a ring having 4 or 5 carbon atoms, which ring optionally contains 1 additional heteroatom independently selected from the group consisting of -O-, -S- and -NR_6-, wherein R_6 is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl or C_{1-6} hydroxyalkyl;

n is 1;

R_1 is C_{1-6} haloalkyl;

X is -O-; and

m is 2.

57. The method according to claim 41, wherein R_3 is  , wherein:

R_9 is optionally-substituted C_{1-6} alkyl, optionally-substituted C_{3-8} cycloalkyl, optionally-substituted C_{6-10} aryl, optionally-substituted heteroaryl or optionally-substituted saturated or partially unsaturated heterocycle;

R_4 and R_5 are independently selected from the group consisting of hydrogen and optionally-substituted C_{1-6} alkyl; and

X is -O-, -S-, -CH_2-O- or -CH_2-S-.

58. The method according to claim 41, wherein R_3 is  , wherein:

R_7 is oxygen;

Z is -NH-;

p is zero, 1, 2 or 3;

R_9 is C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, optionally-substituted C_{5-6} cycloalkyl, optionally-substituted phenyl or optionally-substituted 5- to 6-membered saturated or partially unsaturated heterocycle;

R_4 and R_5 are independently selected from the group consisting of hydrogen, C_{1-6} alkyl and C_{1-6} haloalkyl;

n is 1 or 2;

R_1 is halogen, C_{1-6} alkyl or C_{1-6} haloalkyl;

X is -O- or -S-; and

m is 2 or 3.

59. The method according to claim 41, wherein R_3 is  , wherein:

R_7 is oxygen;

Z is -NH-;

p is zero, 1, 2 or 3;

R_9 is C_{5-6} cycloalkyl, optionally-substituted phenyl or 5- to 6-membered saturated or partially unsaturated heterocycle, wherein the phenyl is substituted with zero, 1 or 2, preferably zero or one, groups independently selected from the group consisting of halogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} hydroxyalkyl, C_{1-6} alkyloxy(C_{1-6})alkyl, amino(C_{1-6})alkyl, hydroxy, nitro and amino;

R_4 and R_5 are independently selected from the group consisting of hydrogen and C_{1-6} alkyl;

n is 1;

R_1 is C_{1-6} haloalkyl;

X is -O-; and

m is 2.

60. The method according to claim 41, wherein said disorder is selected from the group consisting of neuronal damage, acute or chronic pain, neuropathic pain, surgical pain, convulsions, a neurodegenerative condition, manic depression and diabetic neuropathy.

61. The method according to claim 41, wherein said disorder is acute or chronic pain.

62. The method according to claim 41, wherein said disorder is neuropathic pain.

63. The method according to claim 41, wherein said disorder is surgical pain.

64. The method according to claim 41, wherein said disorder is neuronal damage caused by focal or global ischemia.

65. The method according to claim 41, wherein said disorder is a neuro-degenerative condition.

66. The method according to claim 65, wherein said neurodegenerative condition is amyotrophic lateral sclerosis (ALS).

67. The method according to claim 41, wherein said compound functions as an antitinnitus agent, an anticonvulsant, an antiarrhythmic, a local anesthetic or an antimaniac depressant.

68. The method according to claim 41, wherein said mammal is a human, dog or cat.

69. The method according to claim 41, wherein said mammal is a human.

70. A method of making the compound according to claim 1, wherein said method comprises:

(a) reacting in a first step an aryl aldehyde with a primary or secondary amine;

(b) optionally, in a second step, reacting the product of the first step (i) with an acid chloride compound of Formula ***II***:



II

wherein R_7 is oxygen or sulfur, and R_9 is selected from the group consisting of optionally-substituted $C_{1\text{-}6}$ alkyl, an optionally-substituted $C_{3\text{-}8}$ carbocyclic ring system, or an optionally-substituted $C_{6\text{-}10}$ aryl;

(ii) with an isocyanate of Formula ***III***:



III

wherein *p* is an integer from zero to 4, R_7 is oxygen or sulfur, and R_9 is selected from the group consisting of optionally-substituted $C_{1\text{-}6}$ alkyl, an optionally-substituted $C_{3\text{-}8}$ carbocyclic ring system, optionally-substituted $C_{6\text{-}10}$ aryl, optionally-substituted heteroaryl and saturated or partially unsaturated heterocycle;

or (iii) with either triphosgene and triethylamine or thiophosgene and triethylamine, followed by R_9-$(CH_2)_p$-OH, wherein *p* is an integer from zero to 4, and R_9 is selected from the group consisting of optionally-substituted C_{1-6} alkyl, an optionally-substituted C_{3-8} carbocyclic ring system, optionally-substituted C_{6-10} aryl, optionally-substituted heteroaryl and saturated or partially unsaturated heterocycle; and

(c) recovering the product obtained from either of the first or second steps.